Clinical Trial Update: Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Soquelitinib for moderate-to-severe Atopic Dermatitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Soquelitinib

Snippet

Sponsor: Corvus Pharmaceuticals, Inc. | Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Status: RECRUITING